Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CDTX Stock Forecast 2026-2027
$221.38
Current Price
$6.96B
Market Cap
Buy 0
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to CDTX Price Targets
+0.1%
To High Target of $221.50
+0.1%
To Median Target of $221.50
+0.1%
To Low Target of $221.50
CDTX Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+329.9%
1 Year Change
+0.2%
Year-to-Date Change
0.0%
From 52W High of $221.42
+1,354.5%
From 52W Low of $15.22
📊 TOP ANALYST CALLS
Did CDTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cidara is one of their latest high-conviction picks.
Latest CDTX Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, CDTX has a neutral consensus with a median price target of $221.50 (ranging from $221.50 to $221.50). The overall analyst rating is Buy (6.0/10). Currently trading at $221.38, the median forecast implies a 0.1% upside. This outlook is supported by 0 Buy, 6 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CDTX Analyst Ratings
0
Buy
6
Hold
0
Sell
CDTX Price Target Range
Low
$221.50
Average
$221.50
High
$221.50
Current: $221.38
Latest CDTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CDTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 18, 2025 | Guggenheim | Seamus Fernandez | Neutral | Downgrade | $N/A |
| Nov 14, 2025 | HC Wainwright & Co. | Sara Nik | Neutral | Downgrade | $N/A |
| Nov 14, 2025 | Needham | Joseph Stringer | Hold | Downgrade | $N/A |
| Nov 7, 2025 | Needham | Joseph Stringer | Buy | Maintains | $135.00 |
| Nov 7, 2025 | RBC Capital | Brian Abrahams | Outperform | Maintains | $145.00 |
| Oct 21, 2025 | HC Wainwright & Co. | Sara Nik | Buy | Reiterates | $150.00 |
| Oct 16, 2025 | Morgan Stanley | Maxwell Skor | Overweight | Initiates | $190.00 |
| Oct 10, 2025 | JP Morgan | Anupam Rama | Overweight | Initiates | $200.00 |
| Oct 9, 2025 | HC Wainwright & Co. | Sara Nik | Buy | Maintains | $150.00 |
| Oct 9, 2025 | WBB Securities | Steve Brozak | Strong Buy | Maintains | $199.00 |
| Oct 3, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $173.00 |
| Sep 26, 2025 | HC Wainwright & Co. | Sara Nik | Buy | Maintains | $110.00 |
| Sep 25, 2025 | Guggenheim | Seamus Fernandez | Buy | Maintains | $167.00 |
| Sep 24, 2025 | Needham | Joseph Stringer | Buy | Maintains | $100.00 |
| Sep 24, 2025 | WBB Securities | Steve Brozak | Strong Buy | Reiterates | $123.00 |
| Sep 22, 2025 | WBB Securities | Steve Brozak | Strong Buy | Maintains | $123.00 |
| Aug 8, 2025 | Needham | Joseph Stringer | Buy | Maintains | $74.00 |
| Aug 8, 2025 | HC Wainwright & Co. | Sara Nik | Buy | Maintains | $74.00 |
| Aug 8, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $66.00 |
| Jun 30, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $59.00 |
Cidara Therapeutics, Inc. (CDTX) Competitors
The following stocks are similar to Cidara based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cidara Therapeutics, Inc. (CDTX) Financial Data
Cidara Therapeutics, Inc. has a market capitalization of $6.96B with a P/E ratio of -8.3x. The company generates $1.28M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -13,811.9% and return on equity of -68.7%.
Valuation Metrics
Market Cap
$6.96B
Enterprise Value
$6.54B
P/E Ratio
-8.3x
PEG Ratio
-0.3x
Price/Sales
5,460.1x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-13,811.9%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+6.0%
Current Ratio
4.6x
Debt/Equity
0.5x
ROE
-68.7%
ROA
-29.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cidara Therapeutics, Inc. (CDTX) Business Model
About Cidara Therapeutics, Inc.
What They Do
Develops targeted immunotherapies for serious diseases.
Business Model
Cidara Therapeutics operates as a clinical-stage biotechnology company that generates revenue through the development of innovative drug-Fc conjugates (DFCs) aimed at treating infectious diseases and oncology. By leveraging its proprietary Cloudbreak® platform, the company creates therapies that engage the immune system while targeting specific disease mechanisms, thereby addressing unmet medical needs.
Additional Information
Based in San Diego, California, Cidara emphasizes innovation and collaboration, striving to set new standards of care in complex medical conditions. The company's focus on immunotherapy solutions positions it to potentially transform patient care across various healthcare sectors.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
38
CEO
Dr. Jeffrey L. Stein Ph.D.
Country
United States
IPO Year
2015
Website
www.cidara.comCidara Therapeutics, Inc. (CDTX) Latest News & Analysis
Latest News
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?
6 months ago
Quick Summary
HighVista Strategies purchased 70,904 shares of Cidara Therapeutics for $6.79 million, constituting 1.66% of their 13F reportable assets under management.
Why It Matters
HighVista's investment in Cidara Therapeutics signals confidence in the company's potential, potentially influencing other investors and affecting stock performance.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
hVIVO PLC commended Cidara Therapeutics following its $9.2 billion acquisition by MSD, emphasizing that the deal highlights the value of hVIVO's early-stage drug development expertise.
Why It Matters
The acquisition of Cidara Therapeutics by MSD for $9.2 billion underscores hVIVO's value in early-stage drug development, potentially boosting its market perception and attracting investor interest.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
Merck plans to acquire Cidara Therapeutics for approximately $9.2 billion, with hVIVO benefiting from Cidara's lead antiviral, CD388, developed via its trial platform.
Why It Matters
Merck's $9.2 billion acquisition of Cidara highlights hVIVO's role in developing CD388, potentially boosting hVIVO's market perception and investor confidence in its capabilities.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
Cidara Therapeutics has completed enrollment of 6,000 participants in its Phase 3 ANCHOR trial for CD388, a non-vaccine flu preventative, with interim analysis expected in Q1 2026.
Why It Matters
The completion of enrollment in Cidara's Phase 3 trial for CD388 signals progress toward potential market approval, impacting stock valuation and investor interest in biotech innovations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS, and CDTX
7 months ago
Quick Summary
Monteverde & Associates is investigating NuVista Energy Ltd. after recovering millions for shareholders, recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.
Why It Matters
Recognition of Monteverde & Associates signifies credibility in shareholder recovery, potentially impacting NuVista Energy Ltd.'s stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
A fund acquired 520,310 shares of CDTX, increasing its stake to 3,020,990 shares valued at $289.29 million, now the fund's 3rd-largest holding at 19.2% of AUM.
Why It Matters
The significant increase in shares and stake value highlights strong institutional confidence in CDTX, potentially driving demand and influencing stock price positively.
Source: The Motley Fool
Market Sentiment:
Positive
Frequently Asked Questions About CDTX Stock
What is Cidara Therapeutics, Inc.'s (CDTX) stock forecast for 2027?
Based on our analysis of 17 Wall Street analysts, Cidara Therapeutics, Inc. (CDTX) has a median price target of $221.50. The highest price target is $221.50 and the lowest is $221.50.
Is CDTX stock a good investment in 2027?
According to current analyst ratings, CDTX has 0 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $221.38. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CDTX stock?
Wall Street analysts predict CDTX stock could reach $221.50 in the next 12 months. This represents a 0.1% increase from the current price of $221.38. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cidara Therapeutics, Inc.'s business model?
Cidara Therapeutics operates as a clinical-stage biotechnology company that generates revenue through the development of innovative drug-Fc conjugates (DFCs) aimed at treating infectious diseases and oncology. By leveraging its proprietary Cloudbreak® platform, the company creates therapies that engage the immune system while targeting specific disease mechanisms, thereby addressing unmet medical needs.
What is the highest forecasted price for CDTX Cidara Therapeutics, Inc.?
The highest price target for CDTX is $221.50 from at , which represents a 0.1% increase from the current price of $221.38.
What is the lowest forecasted price for CDTX Cidara Therapeutics, Inc.?
The lowest price target for CDTX is $221.50 from at , which represents a 0.1% increase from the current price of $221.38.
What is the overall CDTX consensus from analysts for Cidara Therapeutics, Inc.?
The overall analyst consensus for CDTX is neutral. Out of 17 Wall Street analysts, 0 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $221.50.
How accurate are CDTX stock price projections?
Stock price projections, including those for Cidara Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 13, 2026 3:05 AM UTC